Philadelphia TV host Mike Jerrick discovers he has skin cancer during live on-air broadcast
Mike Jerrick, co-host of 'Good Day Philadelphia' on FOX29, was broadcasting a skin care segment with Dr. Joanna Walker, a dermatologist with the Tara Miller Melanoma Center at the University of Pennsylvania.
As they discussed the importance of checking the skin for signs of cancer, Walker inspected a spot on Jerrick's right elbow, pronouncing that it was basal cell carcinoma, a common type of skin cancer.
'It has all the features of the most common type of skin cancer, which is also very treatable when it's caught early,' Walker said in the segment.
Jerrick expressed surprise, asking, 'What are you going to do to it, burn it off?'
The dermatologist replied that the cancerous spot most likely needs to be 'cut and stitched.'
3 FOX29 'Good Day Philadelphia' host Mike Jerrick has his skin examined by dermatologist Dr. Joanna Walker during an on-air segment.
FOX29
The good news, she said, is that basal cell is a 'very slow-growing type of skin cancer' that's not likely to spread anywhere else on the body.
'But you do need to remove it so it doesn't keep growing and take over normal skin,' Walker advised.
Jerrick spoke with Fox News Digital about the revelation, noting that it was a complete surprise to him.
'I did say that we should have her bring her [micro]scope because I wanted to check out a couple of things on my arms, so that part was planned, but I never really thought it was going to be skin cancer,' he said.
3 The good news, she said, is that basal cell is a 'very slow-growing type of skin cancer' that's not likely to spread anywhere else on the body.
The dermatologist recognized it right away, Jerrick shared.
'When she blurted it out, I didn't get alarmed or anything,' Jerrick said. 'It was just like, 'Oh dang, I should have done this a long time ago.''
'I was more shocked that she said she was going to cut it out instead of burn it off — that's where I got surprised.'
3 As they discussed the importance of checking the skin for signs of cancer, Walker inspected a spot on Jerrick's right elbow, pronouncing that it was basal cell carcinoma, a common type of skin cancer.
FOX29
Jerrick is scheduled to have the cancerous spot removed on Friday.
'I should be fine,' he said. 'She'll just suture me up and I'll be on my way.'
Many people have reached out to thank Jerrick for airing the segment.
To those with similar markings or skin changes, 'it's important to get those checked,' he advised.
Basal cell carcinoma is the most common type of skin cancer, affecting about 3.6 million Americans each year, according to the Skin Cancer Foundation.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Business News
an hour ago
- Time Business News
How Chapter Helps Employers and Healthcare Providers Support Retirees More Effectively
Navigating healthcare in retirement can be overwhelming. With multiple Medicare options, complex enrollment timelines, and a barrage of confusing terms, retirees often feel lost. This confusion doesn't just affect individuals—it places a burden on employers and healthcare providers striving to offer the best support to their retiring employees and patients. Enter Chapter, a tech-enabled platform that's transforming how organizations guide retirees through their Medicare journey. By partnering with Chapter, employers and healthcare providers can provide accurate, unbiased, and highly personalized Medicare guidance, making the retirement transition smoother, more confident, and cost-effective for all parties involved. As millions of Americans approach retirement age every year, the demand for trustworthy Medicare support is at an all-time high. For employers managing retirement benefits or healthcare providers coordinating care, ensuring retirees make the right Medicare choices is crucial for long-term wellness and financial security. Unfortunately, Medicare is not one-size-fits-all. Between Original Medicare, Medicare supplement plan (also known as Medigap plans), Medicare Advantage, and Part D prescription drug plans, the system can be overwhelming. Retirees often end up paying more than necessary or signing up for plans that don't meet their healthcare needs—unless they receive proper guidance. Chapter's B2B platform was created to bridge this gap. It empowers organizations to deliver tailored Medicare navigation services at scale. Whether you're an HR director, a hospital administrator, or a retirement plan advisor, Chapter makes it easy to ensure your retirees receive expert, up-to-date Medicare guidance. Here's how Chapter stands out: Chapter works across all major insurance carriers nationwide. Its licensed Medicare advisors are fiduciary-like in approach, offering objective advice without steering clients toward commission-based plans. This means retirees can explore a full range of Medicare supplement plans, including Medigap plans, with full transparency. Every retiree receives one-on-one assistance from a dedicated Medicare advisor. These experts take into account each individual's health needs, prescription medications, doctor preferences, and financial situation to recommend the most suitable plan. This level of support helps eliminate stress and misinformation during the Medicare enrollment process. Chapter's advanced technology platform compares over 24,000 plan combinations in real time. This allows retirees to view their best Medicare options quickly and clearly—whether they're considering Medigap plans, Part D prescription drug coverage, or Medicare Advantage. By partnering with Chapter, organizations unlock several advantages: Reduced Administrative Burden : HR teams and healthcare staff no longer need to field complex Medicare questions outside their expertise. : HR teams and healthcare staff no longer need to field complex Medicare questions outside their expertise. Improved Retiree Satisfaction : Employees and patients feel supported during one of the most confusing phases of life—retirement. : Employees and patients feel supported during one of the most confusing phases of life—retirement. Stronger Long-Term Relationships : Providing helpful, value-added services like Medicare guidance enhances trust and loyalty. : Providing helpful, value-added services like Medicare guidance enhances trust and loyalty. Better Health Outcomes: When retirees are on the right plan, they're more likely to access the care and medications they need without financial hardship. Many retirees opt for Medicare supplement plans, commonly known as Medigap plan, to cover costs that Original Medicare doesn't—like copayments, coinsurance, and deductibles. Chapter helps retirees understand if a Medigap plan is right for them and compares all available options, ensuring the most value for their health and budget. What sets Medigap apart is its flexibility. Unlike Medicare Advantage, which typically limits provider networks, Medigap plans allow access to any doctor or hospital that accepts Medicare nationwide. This is especially valuable for retirees who travel frequently or need specialized care. Supporting retirees during Medicare enrollment doesn't have to be difficult. With Chapter's B2B solutions, employers and healthcare providers can ensure their retirees get the expert help they need—while saving time, building trust, and improving a world where confusion around Medicare can lead to poor choices and unnecessary expenses, Chapter provides clarity. Whether helping retirees choose a Medigap plan or walking them through the full Medicare supplement plan landscape, Chapter's mission is simple: empower retirees with confidence and clarity. TIME BUSINESS NEWS
CNN
3 hours ago
- CNN
5 things to know for July 21: Flooding, Gaza, Russia-Ukraine, LA crash, Washington Commanders
A system-wide ground stop for all Alaska Airlines and Horizon Air flights was issued on Sunday night due to an IT outage. Although the cause of the outage wasn't released, the flights were halted for more than three hours. In a statement to CNN, the airline warned of further travel disruptions and delays on Monday. Travelers are advised to check their flight status before heading to the airport. Here's what else you need to know to get up to speed and on with your day. This summer has been defined by a tragic surge in deadly flash floods across the US, underscoring the escalating volatility of our warming world. First, there was the devastating Texas floods that occurred on July 4 that killed more than 130 people. Three more people died after flash floods hit Ruidoso, New Mexico, on July 8. Major roads in Chicago were suddenly under water when a 1,000-year rainfall event struck in early July. New York City saw its second-heaviest rainfall total in one hour on July 14. Torrential rains and flooding also hit portions of North Carolina and Kansas City this month. Despite this chain of events, the Trump administration recently paused work on a new database designed to provide Americans with updated estimates about their risk of experiencing flash floods. However, after reporting by CNN and The Washington Post, and discussions between NOAA leadership and Commerce Department officials, NOAA has received permission to move ahead with work on the database At least 76 children and 10 adults have reportedly died of malnutrition in Gaza since the conflict with Israel began in October 2023, the Palestinian health ministry says. According to the World Health Organization, most of those deaths have occurred since Israel imposed a humanitarian aid blockade in March. The latest casualties reflect a deepening crisis in the enclave. Aid agencies say the amount of food, medical supplies and fuel reaching Gaza is far too little to sustain the population. And each day, thousands risk their lives to find something to eat. The Office of the UN High Commissioner for Human Rights said nearly 800 Palestinians were killed while trying to access aid between late May and July 7. Ukrainian President Volodymyr Zelensky has called for talks with Russia this week in an effort to reach a ceasefire deal. 'The dynamics of the negotiations must improve. We need to do everything possible to achieve a ceasefire. The Russian side must stop avoiding decisions regarding prisoner exchanges, the return of children and the cessation of killings,' Zelensky said. Kremlin spokesperson Dmitry Peskov responded by saying that Russia was 'ready to move quickly' on achieving a peace deal with Ukraine, but its 'main goal' was to achieve its 'objectives.' The latest round of talks in Istanbul ended in early June, with Russian and Ukrainian delegates meeting for barely over an hour before calling it quits. Since then, Russia has launched waves of deadly missile and drone strikes at Ukraine. Russia may also be days or weeks away from starting a heightened summer offensive, perhaps using the 160,000 troops Ukrainian officials have said are amassing near their front lines. A man who was reportedly kicked out of a nightclub early Saturday is accused of intentionally driving into a crowd that had gathered outside for valet services, food stands and entry into the hotspot. The crash at The Vermont Hollywood left at least 36 people injured and seven in critical condition. The driver, identified as Fernando Ramirez, 29, was then dragged out of his vehicle by bystanders, beaten and shot in the lower back. Ramirez was transported to the hospital for surgery and arrested on suspicion of assault with a deadly weapon. The man believed to have shot Ramirez remains at large. Mayor Karen Bass called the incident a 'heartbreaking tragedy' and praised the swift response of more than 100 police and fire personnel. President Donald Trump is threatening to restrict a stadium deal in Washington, DC, unless the Washington Commanders change their name back to the 'Redskins.' The football team dropped the old name in 2020 after decades of criticism from Native American groups. But on Sunday, Trump posted on his social media network: 'I may put a restriction on them that if they don't change the name back to the original 'Washington Redskins,' and get rid of the ridiculous moniker, 'Washington Commanders,' I won't make a deal for them to build a Stadium in Washington.' In April, DC Mayor Muriel Bowser announced plans to build a new stadium on federal land at the site of the old Robert F. Kennedy Memorial Stadium and bring the Commanders back to the district. The proposal is currently stalled before the DC Council. CNN has reached out to the Commanders and the DC mayor's office for comment on Trump's posts. GET '5 THINGS' IN YOUR INBOX If your day doesn't start until you're up to speed on the latest headlines, then let us introduce you to your new favorite morning fix. Sign up here for the '5 Things' newsletter. The president claimed that Woodward had released audio from their interviews without his consent and sought nearly $50 million in damages. The giant prop experienced a serious malfunction during the pop star's show in San Francisco. After years of Marvel movies, audiences are up for a little DC action with the Man of Steel. Researchers have finally decoded an error in the 12th-century epic, 'The Song of Wade.' Apparently, the hero doesn't battle elves. And it was all due to one lucky mistake. $14.75 millionThat's how much one famous prop from the 1941 movie, 'Citizen Kane,' sold for at auction. 'I should have just stayed renting.' — Angel Scheid, who purchased her one bedroom, one bathroom Los Angeles home in 2022 for $915,000, with a 5.99% interest rate. She was planning to refinance her mortgage, but interest rates have remained too high. 🌤️ Check your local forecast to see what you can expect. Health Secretary Robert F. Kennedy Jr. and other Trump officials seem open to embracing psychedelics to treat conditions such as trauma, depression and drug addiction. The shift has advocates excited, but some experts worry the hype could be getting ahead of science and safety. In part one of a two-part series, we hear from someone who says a powerful hallucinogen helped kick her drug habit. Today's edition of 5 Things AM was edited and produced by CNN's Andrew Torgan.
Business Wire
13 hours ago
- Business Wire
Cloudbreak Pharma Inc. Announces Positive Phase 2 Results for CBT-004 in Patients with Vascularized Pinguecula
IRVINE, Calif.--(BUSINESS WIRE)--Cloudbreak Pharma Inc. a clinical-stage ophthalmology company developing innovative therapies for ocular surface diseases, today announced positive topline results from its Phase 2 clinical trial evaluating CBT-004 ophthalmic solution in patients with vascularized pinguecula and associated conjunctival hyperemia. "There is a significant unmet need for patients suffering from symptomatic pinguecula, as current therapies are largely off-label and may carry safety concerns with long-term use," said Dr. John Hovanesian, Clinical Professor of Ophthalmology and recognize Share Key Phase 2 Results Primary Endpoint Achieved: Both investigated concentrations of CBT-004 demonstrated statistically significant improvements in conjunctival hyperemia compared to vehicle at Day 28, as assessed by an independent reading center using digital imaging. Rapid Onset and Sustained Efficacy: Significant improvements were observed as early as Day 7 with the highest investigated concentration CBT-004 , with benefits persisting through the 28-day treatment period. Significant Symptom Relief: Both CBT-004 concentrations showed statistically significant improvements in five common patient-reported symptoms including burning/stinging, itching, foreign body sensation, eye discomfort, and pain compared to vehicle. Excellent Safety Profile: No treatment-related adverse events were observed. Most adverse events were mild to moderate. No clinically meaningful changes in visual acuity or intraocular pressure were reported. Addressing a Significant Unmet Medical Need Vascularized pinguecula affects millions of Americans and represents a substantial unmet medical need in ophthalmology. This common, benign conjunctival growth can become problematic when it develops abnormal blood vessels and inflammation, which can lead to persistent redness, irritation, pain, and foreign body sensation. Current management options are limited, with many patients relying on off-label corticosteroids or surgical excision, both of which carry significant limitations and potential complications. Study Design and Results The multicenter, randomized, double-masked, vehicle-controlled Phase 2 study enrolled 88 adult patients with vascularized pinguecula and associated conjunctival hyperemia. Participants were randomized to receive one of two concentrations of CBT-004, or vehicle. The primary endpoint was the change from baseline in conjunctival hyperemia at Day 28, as measured by an independent reading center using standardized digital imaging protocols. Expert Commentary "There is a significant unmet need for patients suffering from symptomatic pinguecula, as current therapies are largely off-label and may carry safety concerns with long-term use," said Dr. John Hovanesian, Clinical Professor of Ophthalmology and recognized key opinion leader in anterior segment disease. "The results from this trial are exciting, as they demonstrate that a targeted, non- steroidal therapy can meaningfully improve both the clinical signs and symptoms that impact patients' quality of life." "As a principal investigator in this study, I was impressed by the consistency and magnitude of improvement in both objective redness and patient-reported discomfort with CBT-004," commented Dr. Sherif El-Harazi, Medical Director at Global Research Management. "The safety profile was excellent, and I believe this therapy could represent a meaningful advance for our patients with vascularized pinguecula." About CBT-004 CBT-004 is a novel, preservative-free topical ophthalmic solution containing a potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptors and platelet-derived growth factor (PDGF) receptors. The formulation is specifically designed to reduce abnormal blood vessel growth and inflammation associated with vascularized pinguecula while minimizing potential ocular surface toxicity through its preservative- free composition. Next Steps and Regulatory Strategy Based on these positive Phase 2 results, Cloudbreak Pharma Inc. plans to advance CBT-004 into Phase 3 development and initiate discussions with the U.S. Food and Drug Administration (FDA) to establish the regulatory pathway toward potential approval. The company anticipates providing updates on Phase 3 study design and timing in the coming months. Market Opportunity The vascularized pinguecula market represents a significant commercial opportunity with limited therapeutic options. The prevalence of pinguecula increases with age and UV exposure, affecting a substantial portion of the aging population. With no FDA-approved treatments specifically indicated for this condition, CBT-004 has the potential to become a category-defining therapy in this underserved market. About Cloudbreak Pharma Inc. Cloudbreak Pharma Inc. is a clinical-stage ophthalmology company dedicated to developing innovative therapies for ocular surface diseases with high unmet medical need. The company's pipeline focuses on novel treatments targeting inflammation, vascularization, and other pathological processes affecting the ocular surface. Cloudbreak is committed to improving outcomes for patients with challenging eye conditions through scientifically-driven therapeutic development. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the potential therapeutic benefits of CBT-004, the company's clinical development plans, regulatory strategy, and market opportunity. These forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause actual results to differ include, but are not limited to, the uncertainty of clinical trial results, regulatory approval processes, competitive developments, and other risks detailed in the company's filings. The company undertakes no obligation to update these forward-looking statements except as required by law. Please note that the information contained in this press release may not be complete. For further details about Cloudbreak Pharma Inc., and our drug candidates, please refer to our company's website (at
